.Attributes Medication, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after an average follow-up of 11 months, clients along with metastatic intestinal lumps who acquired biomarker-matched therapies based on distributing cyst DNA profiling showed a higher clinical benefit than those getting unmatched treatment.